REstart or STop Antithrombotic Randomised Trial in France (RESTART-Fr)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02966119|
Recruitment Status : Terminated (Recruitment difficulties)
First Posted : November 17, 2016
Last Update Posted : May 9, 2022
RESTART- fr is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet medication) for the prevention of vaso-occlusive disease before the ICH.
RESTART- fr is testing whether a policy of starting antiplatelet drugs (one or more of aspirin, clopidogrel, or dipyridamole, chosen at investigator's discretion) results in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet drugs.
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Hemorrhage||Drug: Clopidogrel or Aspirin and/or Dypyridamole||Phase 3|
More than one third of the adults with a stroke due to bleeding into the brain - known as brain haemorrhage - are taking drugs to prevent clotting when they have a brain haemorrhage.
These patients had previously suffered illnesses like angina, heart attack, or stroke due to blood vessel blockage, which is why they are treated with drugs to prevent further clots occurring. These drugs are usually stopped when the brain haemorrhage occurs.
But when patients recover from brain haemorrhage, they and their doctors are often uncertain about whether to restart these drugs to prevent further clots occurring, or whether to avoid them in case they increase the risk of brain haemorrhage happening again.
In this preliminary study of 292 such people who survive a brain haemorrhage, we will study the potentially beneficial effects of three antiplatelet drugs (one or more of aspirin, clopidogrel, or dipyridamole, chosen by the patient's physician) on the risks of heart attack, stroke and other clotting problems as well as their effect on the risk of a brain haemorrhage happening again.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Benefit/Risk Ratio of Restarting or Avoiding Antiplatelet Drugs in Patients Who Had a Spontaneous Intracerebral Hemorrhage While Treated With Antithrombotic Drugs : RESTART-FR Study|
|Actual Study Start Date :||December 7, 2016|
|Actual Primary Completion Date :||December 7, 2019|
|Actual Study Completion Date :||December 7, 2019|
Experimental: Start antiplatelet drug(s)
If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
Drug: Clopidogrel or Aspirin and/or Dypyridamole
The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm " restart"
No Intervention: Avoid antiplatelet drug(s)
If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
- Number of patients with symptomatic intracerebral hemorrhage [ Time Frame: at one year ]Occurrence of a fatal or non-fatal symptomatic ICH proven radiologically at follow-up ( brain CT or MRI) .
- serious fatal vascular events (i.e. followed by death within 30 days ) or non- fatal [ Time Frame: at one year and at the end of follow-up (2 years) ]symptomatic hemorrhagic events, symptomatic ischemic events, stroke of undetermined nature
- Other fatal events [ Time Frame: at one year and at the end of follow-up (2 years) ]Death without pre-defined vascular cause
- Rankin Scale [ Time Frame: 2 years ]modified Rankin Scale: dichotomized mRS 0-1-2 (no dependency) versus 3 or more (dependency or death)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02966119
|Hôpital Roger Salengro, CHRU de Lille|
|Principal Investigator:||Charlotte CORDONNIER, MD, PhD||University Hospital, Lille|